Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Rabeprazole Krka 20mg Gastro-Resistant Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Rabeprazole Krka 20 mg gastro-resistant tablets

Each gastro-resistant tablet contains 20 mg rabeprazole sodium, equivalent to 18.85 mg rabeprazole.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Gastro-resistant tablet

20 mg gastro-resistant tablets are slightly brownish yellow, biconvex, round, tablet diameter approximately 7.2 mm.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Rabeprazole Krka tablets are indicated for the treatment of:

- Active duodenal ulcer
- Active benign gastric ulcer
- Symptomatic erosive or ulcerative gastro-oesophageal reflux disease (GORD)
- Gastro-oesophageal reflux disease long-term management (GORD maintenance)
- Symptomatic treatment of moderate to very severe gastro-oesophageal reflux disease (symptomatic GORD)
- Zollinger-Ellison syndrome
- In combination with appropriate antibacterial therapeutic regimens for the eradication of *Helicobacter pylori* in patients with peptic ulcer disease. See section 4.2.

4.2 Posology and method of administration

<u>Posology</u>

Adults/elderly:

Active duodenal ulcer and active benign gastric ulcer: The recommended oral dose for both active duodenal ulcer and active benign gastric ulcer is 20 mg to be taken once daily in the morning.

Most patients with active duodenal ulcer heal within four weeks. However, a few patients may require an additional four weeks of therapy to achieve healing. Most patients with active benign gastric ulcer heal within six weeks. However again a few patients may require an additional six weeks of therapy to achieve healing.

Erosive or ulcerative gastro-oesophageal reflux disease (GORD): The recommended oral dose for this condition is 20 mg to be taken once daily for four to eight weeks.

Gastro-oesophageal reflux disease long-term management (GORD maintenance): For long-term management, a maintenance dose of Rabeprazole Krka 20 mg or 10 mg once daily can be used depending upon patient response.

Symptomatic treatment of moderate to very severe gastro-oesophageal reflux disease (symptomatic GORD): 10 mg once daily in patients without oesophagitis. If symptom control has not been achieved during four weeks, the patient should be further

13 May 2024 CRN00F64G Page 1 of 9

investigated. Once symptoms have resolved, subsequent symptom control can be achieved using an on-demand regimen taking 10 mg once daily when needed.

Zollinger-Ellison syndrome: The recommended adult starting dose is 60 mg once a day. The dose may be titrated upwards to 120 mg/day based on individual patient needs. Single daily doses up to 100 mg/day may be given. 120 mg dose may require divided doses, 60 mg twice daily. Treatment should continue for as long as clinically indicated.

Eradication of H. pylori: Patients with *H. pylori* infection should be treated with eradication therapy. The following combination given for 7 days is recommended.

Rabeprazole Krka 20 mg twice daily + clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily.

Renal and hepatic impairment: No dosage adjustment is necessary for patients with renal or hepatic impairment.

See section 4.4 Special Warnings and Precautions for Use of Rabeprazole Krka in the treatment of patients with severe hepatic impairment.

Paediatric population

Rabeprazole Krka is not recommended for use in children, as there is no experience of its use in this group.

Method of administration

For indications requiring once daily treatment Rabeprazole Krka tablets should be taken in the morning, before eating; and although neither the time of day nor food intake was shown to have any effect on rabeprazole sodium activity, this regimen will facilitate treatment compliance.

Patients should be cautioned that the Rabeprazole Krka tablets should not be chewed or crushed, but should be swallowed whole.

4.3 Contraindications

Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients listed in section 6.1.

Pregnancy and lactation.

4.4 Special warnings and precautions for use

Symptomatic response to therapy with rabeprazole sodium does not preclude the presence of gastric or oesophageal malignancy, therefore the possibility of malignancy should be excluded prior to commencing treatment with Rabeprazole Krka.

Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance.

A risk of cross-hypersensitivity reactions with substituted benzimidazoles cannot be excluded.

Patients should be cautioned that Rabeprazole Krka tablets should not be chewed or crushed, but should be swallowed whole.

<u>Paediatric population</u>

Rabeprazole Krka is not recommended for use in children, as there is no experience of its use in this group.

There have been post marketing reports of blood dyscrasias (thrombocytopenia and neutropenia). In the majority of cases where an alternative aetiology cannot be identified, the events were uncomplicated and resolved on discontinuation of rabeprazole.

Hepatic enzyme abnormalities have been seen in clinical trials and have also been reported since market authorisation. In the majority of cases where an alternative aetiology cannot be identified, the events were uncomplicated and resolved on discontinuation of rabeprazole.

13 May 2024 CRN00F64G Page 2 of 9

No evidence of significant drug related safety problems was seen in a study of patients with mild to moderate hepatic impairment versus normal age and sex matched controls. However because there are no clinical data on the use of rabeprazole in the treatment of patients with severe hepatic dysfunction the prescriber is advised to exercise caution when treatment with Rabeprazole Krka is first initiated in such patients.

Co-administration of atazanavir with Rabeprazole Krka is not recommended (see section 4.5).

Treatment with proton pump inhibitors, including Rabeprazole Krka, may possibly increase the risk of gastrointestinal infections such as *Salmonella*, *Campylobacter* and *Clostridium difficile* (see section 5.1).

Severe hypomagnesaemia has been reported in patients treated with PPIs like rabeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.

For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.

Proton pump inhibitors, especially if used in high doses and over long durations (> 1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10–40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.

Concomitant use of Rabeprazole with Methotrexate

Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients.

Influence on vitamin B12 absorption

Rabeprazole sodium, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypoor a- chlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed.

Subacute cutaneous lupus erythematosus (SCLE)

Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Rabeprazole Krka. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.

Interference with laboratory tests

Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Rabeprazole Krka treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.

Renal impairment

Acute tubulointerstitial nephritis (TIN) has been observed in patients taking rabeprazole and may occur at any point during rabeprazole therapy (see section 4.8). Acute tubulointerstitial nephritis can progress to renal failure.

Rabeprazole should be discontinued in case of suspected TIN, and appropriate treatment should be promptly initiated.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

4.5 Interaction with other medicinal products and other forms of interaction

13 May 2024 CRN00F64G Page 3 of 9

Rabeprazole sodium produces a profound and long lasting inhibition of gastric acid secretion. An interaction with compounds whose absorption is pH dependent may occur. Co-administration of rabeprazole sodium with ketoconazole or itraconazole may result in a significant decrease in antifungal plasma levels. Therefore individual patients may need to be monitored to determine if a dosage adjustment is necessary when ketoconazole or itraconazole are taken concomitantly with Rabeprazole Krka.

In clinical trials, antacids were used concomitantly with the administration of rabeprazole and, in a specific drug-drug interaction study, no interaction with liquid antacids was observed.

Co-administration of atazanavir 300 mg/ritonavir 100 mg with omeprazole (40 mg once daily) or atazanavir 400 mg with lansoprazole (60 mg once daily) to healthy volunteers resulted in a substantial reduction in atazanavir exposure. The absorption of atazanavir is pH dependent. Although not studied, similar results are expected with other proton pump inhibitors. Therefore PPIs, including rabeprazole, should not be co-administered with atazanavir (see Section 4.4).

Methotrexate

Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no data on the safety of rabeprazole in human pregnancy. Reproduction studies performed in rats and rabbits have revealed no evidence of impaired fertility or harm to the foetus due to rabeprazole sodium, although low foeto-placental transfer occurs in rats. Rabeprazole Krka is contraindicated during pregnancy.

Breast-feeding

It is not known whether rabeprazole sodium is excreted in human breast milk. No studies in lactating women have been performed. Rabeprazole sodium is however excreted in rat mammary secretions. Therefore Rabeprazole Krka should not be used during breast feeding.

4.7 Effects on ability to drive and use machines

Based on the pharmacodynamic properties and the adverse events profile, it is unlikely that Rabeprazole Krka would cause an impairment of driving performance or compromise the ability to use machinery. If however, alertness is impaired due to somnolence, it is recommended that driving and operating complex machinery be avoided.

4.8 Undesirable effects

The most commonly reported adverse drug reactions, during controlled clinical trials with rabeprazole were headache, diarrhoea, abdominal pain, asthenia, flatulence, rash and dry mouth. The majority of adverse events experienced during clinical studies were mild or moderate in severity, and transient in nature.

The following adverse events have been reported from clinical trial and post-marketed experience.

Frequencies are defined as:

- Common (≥ 1/100 to < 1/10)
- Uncommon (≥ 1/1,000 to < 1/100)
- Rare (≥ 1/10,000 to < 1/1,000)
- Very rare (< 1/10,000)
- Not known (cannot be estimated from the available data)

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

System Organ Class	Common	Uncommon	Rare	Very rare	Not known
Infections and	infection				

13 May 2024 CRN00F64G Page 4 of 9

Infestations Immune system Interpretations		Health Products Regulatory Authority						
lymphatic system disorders thrombocytopenia, leucocytosis Immune system disorders Immune system dispression dispression dispressio	infestations							
system disorders disorders disorders Importantion of the partition of disorders Importantion of the properties of the partition of the p	Blood and			neutropenia, leucopenia,				
Immune system disorders Immune system system and bone system and bone disorders Immune system system and bone disorders Immune system system and bone system and bone system and bone disorders Immune system system and bone disorders Immune system system and bone system	lymphatic			thrombocytopenia, leucocytosis				
disorders Metabolism and nutrition disorders Insomnia in provision anorexia hyponatremia, hypomagnesaemia (see section 4.4) Psychiatric disorders insomnia disorders deadache, disorders commolence disorders confusion Vascular disorders Eve disorders Cough, phanyingtis, ministis disorders bronchitis, ministis disorders promoting, nause, and abdominal pain, constipation, flatulence, fundic glad polys (benign) disorders gastritis, stomatitis, taste disturbance microscopic colitis Hepato-biliary disorders Frash, genitarion, flatulence, fundic glad polys (benign) rash, enythema² pruntus, sweating, bullous reactions² erythema² engine, gramps, and price of the hip, wrist or reprince specific pain, estace and bone disorders mon-specific pain, pain, constipation, flatulence fundic glad polys (benign) leg cramps, and pain for the hip, wrist or reprince specific pain, pain, constipation, flatulence fundic glad polys (benign) pruntus, sweating, bullous reactions² erythema multiforme, toxic (TEN), Stevens-Johnson syndrome (SIS) Subacute worth and experimentations (SiS) Musculoskeletal, connective tissue and bone disorders mon-specific pain, pain, pain, engine (see process) and pain for the hip, wrist or reprince (see process) and pain for the hip, wrist or reprince (see process) and pain for the hip, wrist or reprince (see process) and pain for the hip, wrist or reprince (see process) and pain for the hip, wrist or reprince (see process) and pa	system disorders							
Insomia disorders Insomia dispinitational distribance Insomia disorders Insomia distributo distributo di Insomia distr	Immune system			hypersensitivity ^{1,2}				
nutrition disorders Insomnia disorders Insomnia (see section 4.4) (hypomagnessemia (see section 4.4) Psychiatric disorders Insomnia disorders Insomnia depression Confusion Nervous system disorders headache, dizorders somnolence distribution cough, peripheral oedema Assentia disorders cough, phanyngitic, minitis disorders bronchitis, phanyngitic, minitis disorders bronchitis, phanyngitic, minitis disorders disorders dispepsia, quy mouth, ausea, aubdominal pain, constipation, flatulence, fundic gland polys (benign) dyspepsia, quy mouth, ausea, aubdominal pain, constipation, flatulence, fundic gland polys (benign) phantitis, state disturbance microscopic collitis Wisculoskeletal, connective tissue disorders annon-specific pain, back pain disorders mysigia, arthralgia, fracture of the hip, wrist or spine (see section 4.4) pain, arthralgia, fracture of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible infection of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible infection of the hip, wrist or spine (see section 4.4) gynaecomastia Reproductive system and breast disorders asthenia, chest pain, influenza chest pain, chilis, chilis, chilis, chest pain, chilis,	disorders							
disorders Insommia (fiscorders disorders) Insommia (fiscorders) depression (see section 4.4) Nervous system disorders headache, dizziness somnolence dizziness somnolence dizziness per disorders per dipheral oedema Gastrointestinal disorders disorders dibornical pain, constipation, flatulence, flundic gland polyps (berign) dyspepsia, dymouth, eructation polyps (berign) dyspepsia, dymouth, eructation polyps (berign) prash, erythema² pruritus, sweating, bullous reactions² erythema multiforme, toxic experience of the hip, wrist or spine (see section 4.4) Subacute multiforme, toxic experience of the hip, wrist or spine (see section 4.4) cutaneous lupus erythema disorders per dispersion to renal failure) progression to renal failure) gyanacomastia Reportouctive system and breast disorders astheria, chest pain, fillis, chest pain, fillis, chills, chi	Metabolism and			anorexia		hyponatremia,		
Psychiatric disorders Somnomia Nervousness Somnolence Somnol	nutrition					hypomagnesaemia		
disorders headache, dizziness somnolence dizziness 'visual disturbance Image: Common temperature per per per per per per per per per p	disorders					(see section 4.4)		
Network system disorders Somnolence disorders Seperations Somnolence disorders Separatory, thoracic and mediastrial disorders Sespiratory, thoracic and mediastrial pain, constipation, flatulence, fundic gland polyps (benign) Hepato-biliary disorders Skin and subcutaneous tissue disorders Since and bone disorders Since and b	Psychiatric	insomnia	nervousness	depression		confusion		
Eye disorders Vascular Vasc	disorders							
Eye disorders Vascular disorders visual disturbance peripheral oedema Vascular disorders cough, pharyngitis, pharyngitis, rhinitis bronchitis, sinustis pharyngitis, sinustis mediastinal disorders diarrhoea, vomiting, nausea, abdominal pain, constipation, flatulence, fundic gland polyps (benign) dyspepsia, dy mouth, eructation apain, constipation, flatulence, fundic gland polyps (benign) hepatitis, jaundice, hepatic encephalopathy² microscopic colitis Skin and subcutaneous tissue disorders non-specific pain, pain, back pain disorders mon-specific pain, pain, wrist or spine (see section 4.4) myalgia, fracture of the hip, wrist or spine (see section 4.4) myalgia, fracture of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible infection infection Tubulointerstitial nephritis (with possible progression to renal failure) gynaecomastia General disorders asthenia, influenza chest pain, chills, chills, chest pain, chills, chills, chills, chest pain, chills, chills, chest pain, chills, chills, chills, chills, chills, chills, chest pain, chills, chi	Nervous system	headache,	somnolence					
Vascular disorders Cough, pharyngitis, rininitis disorders Castrointestinal disorders Castrointestinal pain, constipation, flatulence, fundic gland polyps (benign) Partitis, simulatis, and polyse (benign) Partitis, simulatis, sate disturbance Castrointestinal pain, constipation, flatulence, fundic gland polyps (benign) Partitis, stomatitis, stomatitis, state disturbance Castrointestinal pain, constipation, flatulence, fundic gland polyps (benign) Partitis, stomatitis, state disturbance Castrointestinal pain, subcutaneous tissue disorders Partitis, stomatitis, state disturbance Castrointestinal pain, polyps (benign) Partitis, stomatitis, stomatitis, state disturbance Castrointestinal pain, polyps (benign) Partitis, stomatitis, stomatitis, state disturbance Castrointestinal pain, polyps (benign) Partitis, stomatitis, stomatitis, stomatitis, state disturbance Castrointestinal pain, polyps (benign) Partitis, stomatitis,	disorders	dizziness						
Vascular disorders cough, pharyngitis, rininitis disorders cough, pharyngitis, rininitis sinusitis rininitis disorders bronchitis, sinusitis rininitis sinusitis rininitis disorders bronchitis, sinusitis rininitis sinusitis rininitis disorders diarrhoea, dyspepsia, dymouth, eructation al pain, constipation, flatulence, fundic gland polyps (benign) gastritis, stomatitis, stomatitis, dry mouth, eructation al pain, constipation, flatulence, fundic gland polyps (benign) phepatitis, jaundice, hepatic encephalopathy² erythema² subsculosa, pain, erythema² prash, erythema² pruritus, sweating, bullous reactions² and pression to renal failure) erythema multiforme, consecutive to sic epidermal, eracitysis (TEN), Stevens-Jo hnson syndrome (SJS) Subacute exprimentationsus (see section 4.4) Renal and urinary disorders mon-specific pain, back pain disorders mon-specific pain, pain, pain, pain, erythema infection infection Tubulointerstitial nephritis (with possible infection progression to renal failure) Tubulointerstitial nephritis (with possible infection progression to renal failure) gynaecomastia Renal and urinary tract gisterand breast disorders asthenia, influenza chest pain, chills, chills, chest pain, chills, chest pain, chills, asthenia, chills, chills, gynaecomastia	Eye disorders			visual disturbance				
disorders Respiratory, thoracic and mediastinal disorders cough, pharyngitis, sinusitis rimitits bronchitis, sinusitis rimitits disorders microscopic colitis Gastrointestinal disorders diarrhoea, vomiting, nausea, abdominal pain, constipation, flatulence, fundic gland polyps (benign) disorders passage and both polyps (benign) bepatitis, jaundice, hepatic encephalopathy³ erythema Subacute multiforme, toxic epidemal necrolysis (TEN), Stevens-Johnson syndrome (SJS) Subacute would and execution 4.4) Musculoskeletal, connective tissue and bone disorders pain, back pain disorders leg cramps, arthralgia, fracture of the hip, wrist or spine (see section 4.4) leg cramps, arthralgia, fracture of the hip, erythema infection Tubulointerstitial nephritis (with possible progression to renal failure) Tubulointerstitial nephritis (with possible progression to renal failure) gynaecomastia Reproductive system and breast disorders asthenia, influenza chest pain, chest pain, chillis, chest pain, chest pain, chillis, chest pain, chillis,						peripheral oedema		
thoracic and mediastrial disorders Gastrointestinal disorders Adisorders Ad	disorders					' '		
thoracic and mediastrial disorders Gastrointestinal disorders Adisphage and behaving the inititis withints with disorders Gastrointestinal disorders Adisphage and behaving the inititis within the inititis of the inititis within the inititis, taste disturbance whether the state disturbance whether the interest whether the inititis with the inititis, taste disturbance whether the interest was the disturbance and the propriet whether the propriet whether the inititis, taste disturbance whether the interest was the disturbance and substitute of the injury with the propriet whether the inititis, taste disturbance whether the disturbance and state whether the interest was a disturbance and state whether the interest was a single state disturbance and state whether the interest was a single state disturbance and state whether the propriet was a state disturbance and state whether the propriet was a state disturbance and state whether the propriet was a state disturbance and state whether the propriet was a state disturbance and state whether the propriet was a state of the interest was a state of the interest was a state of the int		cough,	bronchitis,					
Mediastinal disorders rhinitis dyspepsia, dry mouth, eructation abdominal pain, constipation, flatulence, fundic gland polyps (benign) disorders disorders microscopic collitis aste disturbance Skin and subcutaneous tissue disorders subcutaneous tissue and bone disorders mon-specific spain, pain, erythema² pruritus, sweating, bullous reactions² erythema multiforme, toxic epidermal necrolysis (TEN), Stevens-John syndrome (SJS) Subacute cutaneous lupus erythematosus (see section 4.4) Musculoskeletal, connective tissue and bone disorders pain, back pain wrist or spine (see section 4.4) myalgia, fracture of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure) Tubulointerstitial nephritis (with possible progression to renal failure) gynaecomastia Reproductive system and breast disorders asthenia, disorders chest pain, chest pain, chills, Tubulointerstitial nephritis (with possible progression to renal failure) gynaecomastia General disorders and influenza asthenia, chills, chest pain, chills,		_	-					
disorders diarrhoea, vomiting, nausea, abdominal pain, polyps (benign) dyspepsia, dry mouth, eructation abdominal pain, polyps (benign) depatitis, jaundice, hepatitis, jaundice, hepatitis								
Gastrointestinal disorders diarrhoea, vomiting, nause, abdominal pain, constipation, flatulence, fundic gland polyps (benign) hepatitis, jaundice, hepatic encephalopathy² pruritus, sweating, bullous reactions² epidermal subcutaneous tissue disorders non-specific connective tissue and bone disorders non-specific pain, back pain disorders back pain disorders pain, back pain disorders pain, back pain disorders progression to renal failure) Tubulointerstitial nephritis (with possible infection disorders progression to renal failure) progression to renal failure) progression to renal failure progression to renal failur								
disorders vomiting, nausea, abdominal pain, constipation, flatulence, fundic gland polyps (benign) taste disturbance legaration, flatulence, fundic gland polyps (benign) hepatitis, jaundice, hepatic encephalopathy² erythema Skin and subcutaneous tissue disorders rash, erythema² pruritus, sweating, bullous reactions² erythema multiforme, toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS) cutaneous lupus erythematosus (see section 4.4) Musculoskeletal, connective tissue and bone disorders back pain, back pain disorders mon-specific pain, back pain ege cramps, arthralgia, fracture of the hip, wrist or spine (see section 4.4) leg cramps, arthralgia, fracture of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible infection disorders Tubulointerstitial nephritis (with possible infection progression to renal failure) gynaecomastia Reproductive system and breast disorders asthenia, influenza chest pain, chills,	Gastrointestinal	diarrhoea,	dyspepsia,	gastritis, stomatitis,		microscopic colitis		
nausea, abdominal pain, constipation, flatulence, fundic gland polyps (benign) Hepato-biliary disorders Skin and subcutaneous tissue disorders Musculoskeletal, connective tissue and bone disorders Renal and urinary disorders Renal and urinary disorders Renal and urinary disorders Reproductive system and breast disorders and influenza challenge and the first or system and breast disorders and influenza challenge and the first or spine (see section 4.4) apan, back pain abdominal pain, constipation, flatulence, fundic gland polyps (benign) hepatitis, jaundice, hepatic encephalopathy ³ pruritus, sweating, bullous reactions ² erythema multiforme, toxic epidermal necrolysis (TEN), Stevens-Jo historios syndrome (SJS) hepatitis, jaundice, hepatic encephalopathy ³ pruritus, sweating, bullous reactions ² pruri		·	1	1 ~		,		
abdominal pain, constipation, flatulence, fundic gland polyps (benign) Hepato-biliary disorders Skin and subcutaneous tissue disorders Musculoskeletal, connective tissue and bone disorders Renal and urinary disorders Reproductive system and breast disorders and life to get mand feats and breast disorders abdominal pain, constipation, flatulence, fundic gland polyps (benign) hepatitis, jaundice, hepatic encephalopathy³ pruritus, sweating, bullous reactions² erythema multiforme, toxic epidermal necrolysis (TEN), Stevens-Jo hnson syndrome (SJS) (SJS) Musculoskeletal, connective tissue and bone disorders Tubulointerstitial nephritis (with possible progression to renal failure) Tubulointerstitial nephritis (with possible progression to renal failure) gynaecomastia gynaecomastia gynaecomastia			_					
Pain, constipation, flatulence, fundic gland polyps (benign) Paint learning (benign) Paint								
Constipation, flatulence, fundic gland polyps (benign)								
Hepato-billary disorders Skin and subcutaneous tissue disorders Musculoskeletal, connective tissue and bone disorders Musculoskeletal, pain, back pain disorders Pack pain (see section 4.4)		l ·						
Hepato-biliary disorders		•						
Pepato-biliary disorders		· ·						
Hepato-biliary disorders Skin and subcutaneous tissue disorders Musculoskeletal, connective tissue and bone disorders Musculoskeletal, connective tissue and bone disorders Renal and urinary disorders Reproductive system and breast disorders Ash privitus, sweating, bullous reactions² Pruritus, sweating, bull		_						
Hepato-biliary disorders								
disorders Image: Company of the patric stricts and subcutaneous tissue disorders Image: Company of the patric stricts and subcutaneous tissue disorders Image: Company of the patric stricts and subcutaneous tissue disorders Image: Company of the patric stricts and subcutaneous tissue disorders Image: Company of the patric stricts and subcutaneous servitions and subcutaneous stricts and subcutaneous servitions and subcutaneous servitions and subcutaneous servitions and subcutaneous servitions. The patricts are subcutaneous servitions and subcutaneous servitions and subcutaneous servitions. The patricts are subcutaneous servitions. T	Hepato-biliary			hepatitis,				
Skin and subcutaneous tissue disorders rash, erythema² pruritus, sweating, bullous reactions² erythema multiforme, toxic epidermal necrolysis (TEN), Stevens-Jo hnson syndrome (SJS) Stevens-Jo hnson syndrome (SJS) Connective pidermal necrolysis (TEN), Stevens-Jo hnson syndrome (SJS) mon-specific pain, back pain, arthralgia, fracture of the hip, wrist or spine (see section 4.4) Image: section 4.4 (SJS) Image: sect	1 -			I				
subcutaneous tissue disorders erythema² erythema² multiforme, toxic epidermal necrolysis (TEN), Stevens-Jo hnson syndrome (SJS) cutaneous lupus erythematosus (see section 4.4) Musculoskeletal, connective tissue and bone disorders mon-specific pain, back pain tissue and bone disorders myalgia, leg cramps, arthralgia, arthralgia, fracture of the hip, wrist or spine (see section 4.4) response (see section 4.4) Renal and urinary disorders urinary tract infection Tubulointerstitial nephritis (with possible progression to renal failure) Tubulointerstitial nephritis (with possible progression to renal failure) gynaecomastia General disorders asthenia, influenza chest pain, chills, chills, chills, chest pain, chills, chills, chills, chills, chills, chest pain, cutaneous lupus erythematosus (see section 4.4)	Skin and		rash,	pruritus, sweating, bullous reactions ²	erythema	Subacute		
Musculoskeletal, connective tissue and bone disorders Renal and urinary disorders Reproductive system and breast disorders Reproductive system and breast disorders General disorders Amon-specific pain, leg cramps, arthralgia, fracture of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure) General asthenia, influenza chest pain, cheills, chest pain, chills, chills, chills, chest pain, chest pain, chest pain, chills, chest pain, chills, chest pain, chills, chest pain, chills, chest pain, chest pa	subcutaneous		erythema ²			cutaneous lupus		
Musculoskeletal, connective tissue and bone disorders Renal and urinary disorders Reproductive system and breast disorders Reproductive system and breast disorders Renal and urinary disorders Reproductive system and breast disorders Renal and urinary disorders Renal and urinary classes as thenia, influenza asthenia, chills, chest pain, c	tissue disorders		_		toxic	erythematosus (see		
Musculoskeletal, connective tissue and bone disorders Renal and urinary disorders Reproductive system and breast disorders Reproductive system and breast disorders Renal and urinary disorders Reproductive system and breast disorders Renal and urinary disorders Renal and urinary disorders Reproductive system and breast disorders Renal and urinary disorders Reproductive system and breast disorders Renal and urinary disorders Reproductive system and breast disorders Renal and urinary disorders Renal and urinary tract infection Renal and urinary tract infecti					epidermal	section 4.4)		
Musculoskeletal, connective tissue and bone disordersnon-specific pain, back pain disordersmyalgia, leg cramps, arthralgia, fracture of the hip, wrist or spine (see section 4.4)Tubulointerstitial nephritis (with possible progression to renal failure)Image: Connective connective pain, back pain arthralgia, fracture of the hip, wrist or spine (see section 4.4)Renal and urinary disordersurinary tract infectionTubulointerstitial nephritis (with possible progression to renal failure)Image: Connective progression to renal failure)gynaecomastiaReproductive system and breast disordersasthenia, influenzachest pain, chills, chills,chest pain, chills,chest pain, chills,chest pain, chills,					l '			
Musculoskeletal, connective tissue and bone disorders Renal and urinary disorders Reproductive system and breast disorders General disorders Amon-specific pain, back pain and pain, back pain back pain back pain as the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure) Tubulointerstitial nephritis (with possible progression to renal failure) General disorders Assthenia, influenza Assthenia, influenza Chest pain, back pain arguments arguments (SJS) Tubulointerstitial nephritis (with possible progression to renal failure) General disorders Assthenia, influenza Chest pain, chills, chest pain, chills, chest pain, chills,					(TEN),			
Musculoskeletal, connective tissue and bone disordersmyalgia, pain, back pain disordersmyalgia, practure of the hip, wrist or spine (see section 4.4)myalgia, practure of the hip, wrist or spine (see section 4.4)Renal and urinary disordersurinary tract infectionTubulointerstitial nephritis (with possible progression to renal failure)gynaecomastiaReproductive system and breast disordersasthenia, influenzachest pain, chills,chest pain, chills,chest pain, chills,					Stevens-Jo			
Musculoskeletal, connective tissue and bone disorders Renal and urinary disorders Reproductive system and breast disorders General disorders and sathenia, influenza influenza characters Myalgia, leg cramps, arthralgia, fracture of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure) Gisplane (SJS) Myalgia, leg cramps, arthralgia, fracture of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure) General disorders General on the first of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure) General on the first of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure)					hnson			
Musculoskeletal, connective tissue and bone disordersnon-specific pain, back pain back pain, back pain iffluenzamyalgia, leg cramps, arthralgia, fracture of the hip, wrist or spine (see section 4.4)Renal and urinary disordersurinary tract infectionTubulointerstitial nephritis (with possible progression to renal failure)Reproductive system and breast disordersasthenia, influenzachest pain, chills, chills,					syndrome			
connective tissue and bone disorders pain, back pain back pain back pain back pain back pain fracture of the hip, wrist or spine (see section 4.4) Renal and urinary disorders Reproductive system and breast disorders General disorders and bright pain, back pain leg cramps, arthralgia, fracture of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure) gynaecomastia gynaecomastia					1 -			
connective tissue and bone disorders Pain, back pain Pain, p	Musculoskeletal,	non-specific	myalgia,					
tissue and bone disorders back pain arthralgia, fracture of the hip, wrist or spine (see section 4.4) Renal and urinary disorders Reproductive system and breast disorders General disorders and back pain arthralgia, fracture of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure) gynaecomastia gynaecomastia	connective							
disorders fracture of the hip, wrist or spine (see section 4.4) Renal and urinary disorders Fracture of the hip, wrist or spine (see section 4.4) Reproductive system and breast disorders General disorders and influenza Chest pain, chills, fracture of the hip, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure) gynaecomastia	tissue and bone	1 '						
wrist or spine (see section 4.4) Renal and urinary tract infection progression to renal failure) Reproductive system and breast disorders General disorders and influenza chills, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure) gynaecomastia gynaecomastia	disorders		_					
wrist or spine (see section 4.4) Renal and urinary tract infection progression to renal failure) Reproductive system and breast disorders General disorders and influenza chills, wrist or spine (see section 4.4) Tubulointerstitial nephritis (with possible progression to renal failure) gynaecomastia gynaecomastia			the hip,					
Renal and urinary tract infection progression to renal failure) Reproductive system and breast disorders General disorders and influenza chills,								
Renal and urinary tract infection progression to renal failure) Reproductive system and breast disorders General disorders and influenza chills,			spine (see					
urinary disorders infection progression to renal failure) Reproductive system and breast disorders gynaecomastia General disorders and asthenia, influenza chest pain, chills,			•					
disorders gynaecomastia Reproductive system and breast disorders chest pain, disorders and influenza chills,	Renal and		urinary tract	Tubulointerstitial nephritis (with possible				
Reproductive system and breast disorders General disorders and influenza chills, General chills, General chills, General chills,	urinary		infection	progression to renal failure)				
system and breast disorders General asthenia, chest pain, disorders and influenza chills,	disorders							
breast disorders L General disorders and influenza chest pain, chills,	Reproductive					gynaecomastia		
General disorders and asthenia, influenza chest pain, chills,								
disorders and influenza chills,	breast disorders							
	General	asthenia,	chest pain,					
administration like illness pyrexia	disorders and	influenza	chills,					
, , , , , , , , , , , , , , , , , , ,	administration	like illness	pyrexia					

site conditions			
Investigations	increased	weight increased	
	hepatic		
	enzymes ³		

¹Includes facial swelling, hypotension and dyspnoea

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Website: www.hpra.ie.

4.9 Overdose

Experience to date with deliberate or accidental overdose is limited. The maximum established exposure has not exceeded 60 mg twice daily, or 160 mg once daily. Effects are generally minimal, representative of the known adverse event profile and reversible without further medical intervention. No specific antidote is known. Rabeprazole sodium is extensively protein bound and is, therefore, not dialysable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: drugs for acid related disorders, proton pump inhibitors, ATC code: A02BC04.

Mechanism of action

Rabeprazole sodium belongs to the class of anti-secretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H_2 histamine antagonist properties, but suppress gastric acid secretion by the specific inhibition of the H^+/K^+ -ATPase enzyme (the acid or proton pump) The effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Animal studies indicate that after administration, rabeprazole sodium rapidly disappears from both the plasma and gastric mucosa. As a weak base, rabeprazole is rapidly absorbed following all doses and is concentrated in the acid environment of the parietal cells. Rabeprazole is converted to the active sulphenamide form through protonation and it subsequently reacts with the available cysteines on the proton pump.

Pharmacodynamic effects

Anti-secretory Activity: After oral administration of a 20 mg dose of rabeprazole sodium the onset of the anti-secretory effect occurs within one hour, with the maximum effect occurring within two to four hours. Inhibition of basal and food stimulated acid secretion 23 hours after the first dose of rabeprazole sodium are 69% and 82% respectively and the duration of inhibition lasts up to 48 hours. The inhibitory effect of rabeprazole sodium on acid secretion increases slightly with repeated once-daily dosing, achieving steady state inhibition after three days. When the drug is discontinued, secretory activity normalises over 2 to 3 days.

Decreased gastric acidity due to any means, including proton pump inhibitors such as rabeprazole, increases counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may possibly increase the risk of gastrointestinal infections such as *Salmonella*, *Campylobacter* and *Clostridium difficile*.

Serum Gastrin Effects: In clinical studies patients were treated once daily with 10 or 20 mg rabeprazole sodium, for up to 43 months duration. Serum gastrin levels increased during the first 2 to 8 weeks reflecting the inhibitory effects on acid secretion and remained stable while treatment was continued. Gastrin values returned to pre-treatment levels, usually within 1 to 2 weeks after discontinuation of therapy.

13 May 2024 CRN00F64G Page 6 of 9

²Erythema, bullous reactions and hypersensitivity reactions have usually resolved after discontinuation of therapy.

³Rare reports of hepatic encephalopathy have been received in patients with underlying cirrhosis. In treatment of patients with severe hepatic dysfunction the prescriber is advised to exercise caution when treatment with Rabeprazole Krka is first initiated in such patients (see section 4.4).

During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours.

Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.

Human gastric biopsy specimens from the antrum and the fundus from over 500 patients receiving rabeprazole or comparator treatment for up to 8 weeks have not detected changes in ECL cell histology, degree of gastritis, incidence of atrophic gastritis, intestinal metaplasia or distribution of *H. pylori* infection. In over 250 patients followed for 36 months of continuous therapy, no significant change in findings present at baseline was observed.

Other Effects: Systemic effects of rabeprazole sodium in the CNS, cardiovascular and respiratory systems have not been found to date. Rabeprazole sodium, given in oral doses of 20 mg for 2 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, oestrogen, testosterone, prolactin, cholecystokinin, secretin, glucagon, follicle stimulating hormone (FSH), luteinising hormone (LH), renin, aldosterone or somatotrophic hormone.

Clinical efficacy and safety

Studies in healthy subjects have shown that rabeprazole sodium does not have clinically significant interactions with amoxicillin. Rabeprazole does not adversely influence plasma concentrations of amoxicillin or clarithromycin when co-administered for the purpose of eradicating upper gastrointestinal *H. pylori* infection.

5.2 Pharmacokinetic properties

Absorption: Rabeprazole Krka is an enteric-coated (gastro-resistant) tablet formulation of rabeprazole sodium. This presentation is necessary because rabeprazole is acid-labile. Absorption of rabeprazole therefore begins only after the tablet leaves the stomach. Absorption is rapid, with peak plasma levels of rabeprazole occurring approximately 3.5 hours after a 20 mg dose. Peak plasma concentrations (C_{max}) of rabeprazole and AUC are linear over the dose range of 10 mg to 40 mg. Absolute bioavailability of an oral 20 mg dose (compared to intravenous administration) is about 52% due in large part to pre-systemic metabolism. Additionally the bioavailability does not appear to increase with repeat administration. In healthy subjects the plasma half-life is approximately one hour (range 0.7 to 1.5 hours), and the total body clearance is estimated to be 283 \pm 98 ml/min. There was no clinically relevant interaction with food. Neither food nor the time of day of administration of the treatment affect the absorption of rabeprazole sodium.

Distribution: Rabeprazole is approximately 97% bound to human plasma proteins.

Biotransformation and elimination: Rabeprazole sodium, as is the case with other members of the proton pump inhibitor (PPI) class of compounds, is metabolised through the cytochrome P450 (CYP450) hepatic drug metabolising system. *In vitro* studies with human liver microsomes indicated that rabeprazole sodium is metabolised by isoenzymes of CYP450 (CYP2C19 and CYP3A4). In these studies, at expected human plasma concentrations rabeprazole neither induces nor inhibits CYP3A4; and although *in vitro* studies may not always be predictive of *in vivo* status these findings indicate that no interaction is expected between rabeprazole and cyclosporin. In humans the thioether (M1) and carboxylic acid (M6) are the main plasma metabolites with the sulphone (M2), desmethyl-thioether (M4) and mercapturic acid conjugate (M5) minor metabolites observed at lower levels. Only the desmethyl metabolite (M3) has a small amount of anti-secretory activity, but it is not present in plasma.

Following a single 20 mg ¹⁴C labelled oral dose of rabeprazole sodium, no unchanged drug was excreted in the urine. Approximately 90% of the dose was eliminated in urine mainly as the two metabolites: a mercapturic acid conjugate (M5) and a carboxylic acid (M6), plus two unknown metabolites. The remainder of the dose was recovered in faeces.

Gender: Adjusted for body mass and height, there are no significant gender differences in pharmacokinetic parameters following a single 20 mg dose of rabeprazole.

Renal impairment:In patients with stable, end-stage, renal failure requiring maintenance haemodialysis (creatinine clearance \leq 5 ml/min/1.73 m²), the disposition of rabeprazole was very similar to that in healthy volunteers. The AUC and the C_{max} in these patients was about 35% lower than the corresponding parameters in healthy volunteers. The mean half-life of rabeprazole was 0.82 hours in healthy volunteers, 0.95 hours in patients during haemodialysis and 3.6 hours post dialysis. The clearance of the drug in patients with renal disease requiring maintenance haemodialysis was approximately twice that in healthy volunteers.

13 May 2024 CRN00F64G Page 7 of 9

<u>Hepatic impairment:</u> Following a single 20 mg dose of rabeprazole to patients with chronic mild to moderate hepatic impairment the AUC doubled and there was a 2-3 fold increase in half-life of rabeprazole compared to the healthy volunteers. However, following a 20 mg dose daily for 7 days the AUC had increased to only 1.5-fold and the C_{max} to only 1.2-fold. The half-life of rabeprazole in patients with hepatic impairment was 12.3 hours compared to 2.1 hours in healthy volunteers. The pharmacodynamic response (gastric pH control) in the two groups was clinically comparable.

<u>Elderly:</u> Elimination of rabeprazole was somewhat decreased in the elderly. Following 7 days of daily dosing with 20 mg of rabeprazole sodium, the AUC approximately doubled, the C_{max} increased by 60% and $t\frac{1}{2}$ increased by approximately 30% as compared to young healthy volunteers. However there was no evidence of rabeprazole accumulation.

Other special populations

CYP2C19 Polymorphism: Following a 20 mg daily dose of rabeprazole for 7 days, CYP2C19 slow metabolisers, had AUC and $t\frac{1}{2}$ which were approximately 1.9 and 1.6 times the corresponding parameters in extensive metabolisers whilst C_{max} had increased by only 40%.

5.3 Preclinical safety data

Non-clinical effects were observed only at exposures sufficiently in excess of the maximum human exposure that make concerns for human safety negligible in respect of animal data.

Studies on mutagenicity gave equivocal results. Tests in mouse lymphoma cell line were positive, but *in vivo* micronucleus and *in vivo* and *in vitro* DNA repair tests were negative. Carcinogenicity studies revealed no special hazard for humans.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core:

Mannitol (E421)

Magnesium oxide, light (E530)

Hydroxypropylcellulose (E463)

Hydroxypropylcellulose, low-substituted (E463)

Magnesium stearate (E470b)

Coating:

Ethylcellulose (E462)

Magnesium oxide, light (E530)

Hypromellose phthalate

Diacetylated monoglycerides (E472a)

Talc (E553b)

Titanium dioxide (E171)

Yellow iron oxide (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Store in the original package in order to protect from moisture and light. Do not store above 30°C.

6.5 Nature and contents of container

13 May 2024 CRN00F64G Page 8 of 9

Pack sizes (blister of OPA/Alu/PVC film and aluminium foil): 7, 10, 14, 15, 28, 30, 56, 60, 90, 98 and 100 gastro-resistant tablets in a box. Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

KRKA, d.d., Novo mesto Šmarješka cesta 6 8501 Novo mesto Slovenia

8 MARKETING AUTHORISATION NUMBER

PA1347/030/002

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of First Authorisation: 9th August 2013

Date of Last Renewal: 1st July 2015

10 DATE OF REVISION OF THE TEXT

May 2024

13 May 2024 CRN00F64G Page 9 of 9